- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
53
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
53 companies
Ionis Pharmaceuticals
Market Cap: US$13.0b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$80.29
7D
5.2%
1Y
131.0%
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
Legend Biotech
Market Cap: US$3.6b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$19.01
7D
-14.1%
1Y
-48.5%
KalVista Pharmaceuticals
Market Cap: US$836.0m
A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
KALV
US$16.02
7D
9.7%
1Y
86.1%
GeoVax Labs
Market Cap: US$4.9m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GOVX
US$3.15
7D
5.4%
1Y
-93.9%
Arcturus Therapeutics Holdings
Market Cap: US$215.7m
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
ARCT
US$7.53
7D
3.3%
1Y
-56.0%
Geron
Market Cap: US$900.1m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.38
7D
5.3%
1Y
-54.2%
Aprea Therapeutics
Market Cap: US$5.9m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$0.83
7D
-6.7%
1Y
-80.2%
Celcuity
Market Cap: US$5.1b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$110.05
7D
2.9%
1Y
863.7%
Zai Lab
Market Cap: US$2.0b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$18.33
7D
-1.3%
1Y
-30.2%
Heron Therapeutics
Market Cap: US$265.9m
A commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
HRTX
US$1.42
7D
-4.7%
1Y
-22.4%
Dynavax Technologies
Market Cap: US$1.8b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$15.51
7D
-0.8%
1Y
21.7%
Assembly Biosciences
Market Cap: US$436.9m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$28.01
7D
-4.6%
1Y
89.6%
Immunocore Holdings
Market Cap: US$1.8b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$35.11
7D
5.3%
1Y
6.4%
Mirum Pharmaceuticals
Market Cap: US$5.0b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$94.29
7D
3.6%
1Y
98.4%
Natera
Market Cap: US$33.6b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$241.58
7D
4.5%
1Y
44.1%
Akebia Therapeutics
Market Cap: US$382.1m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$1.36
7D
0%
1Y
-42.9%